RELT expression correlates strongly with many immune checkpoint blockade (ICBs) targets such as CTLA-4, TGF-β, PD-L2, in many cancers such as renal cell carcinoma [75] and prostate cancer [69], as mentioned previously. Here, RELT is linked to renal cell carcinoma.